2008-10-20

“We are very pleased to add China Healthcare Partnership as our new investor in Chemclin,” said Mr. Xitang Ying, CEO of Chemclin. “The international healthcare management experience and great support of these top tier investors will undoubtedly strengthen our position to become a leader in China’s diagnostic market and be of great assistance as we build a global diagnostics company.” he added.

This is the first private equity investment of the newly launched China Healthcare Partnership, which is a partnership managed by MC China, a MC Group company. “Of the many healthcare-related companies we’ve looked at, this is one of the rare ones that meets our quality requirements,” said Vicky Yun Chen, a Partner at China Healthcare Partnership. “In addition to its broad diagnostics product offerings, the company has a solid technology background and has built an extensive distribution network for its large product/reagents offering in Chemiluminescence Immunoassays (CLIA) diagnostics, an in-vitro diagnostic method that is more advanced than the commonly used Enzyme-Linked ImmunoSorbent Assay (ELISA) in China. Chemclin was the first company in China to launch a full panel of chemiluminesence diagnostics for blood borne diseases, including the acquired immunodeficiency syndrome (AIDS), syphilis, hepatitis C, and hepatitis B, and also carries a breadth of tumor diagnostic panels. Chemclin’s products have gained wide acceptance and high recognition by the Chinese healthcare community. Most importantly, the company has a credible and capable management team that is essential in building a successful company with sustainable growth in China. We are very pleased to be joining fellow investors WI Harper, Siemens Venture Capital and SB Venture Capital in this exciting time in Chemclin’s development.”

About Beijing Chemclin Biotech / China Diagnostics

Beijing Chemclin Biotech Co., Ltd. (Chemclin) was established in 1999, and has emerged as one of China’s leading diagnostics companies with its own development, manufacturing and distribution headquartered in Beijing. Chemclin develops chemiluminescence immunoassay (CLIA) systems, as well as radioimmunoassay (RIA) kits and clinical chemistry assay kits. Chemclin has more than 130 products fully registered with China’s State of Food and Drug Administration, and has a specialty in infectious disease and tumor diagnostics. It also has a well-established marketing and sales network across China with a presence in 30 provinces, more than 2000 local districts and 30,000 towns. With its CE certification of its assays, Chemclin is now expanding into international markets. More information can be found at: http://www.chemclin.com.